Palvella Therapeutics (PVLA) vs Zymeworks (ZYME)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Zymeworks (ZYME) over the past year, gaining 84.7% versus a gain of 60.8%. Over five years, ZYME leads with a +2.3% price change compared with -63.8% for PVLA. Zymeworks is the larger company by market cap ($1.90 billion vs $1.88 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | ZYME |
|---|---|---|
| Share price | $130.59 | $26.53 |
| Market cap | $1.88B | $1.90B |
| 1-day change | +2.02% | +3.43% |
| YTD return | +24.76% | +0.76% |
| 1-year return | +84.66% | +60.79% |
| 5-year return | -63.81% | +2.27% |
| Forward P/E | — | 30.43 |
| EPS (TTM) | $-4.94 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $161.38 | $31.34 |
| 52-week low | $65.93 | $16.00 |
| Distance from 52-week high | -19.08% | -15.35% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +76.53% | +55.33% |
| Average volume | 213.34K | 673.06K |
| Shares outstanding | 14.41M | 71.20M |
| Employees | 29 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed ZYME by 23.9 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Zymeworks
ZYME stock →Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 231 employees
PVLA vs ZYME FAQ
Which is bigger, Palvella Therapeutics or Zymeworks?
Zymeworks (ZYME) is larger, with a market capitalization of $1.90B compared with $1.88B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, PVLA or ZYME?
PVLA returned +84.66% over the past 12 months, compared with +60.79% for ZYME (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Zymeworks in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.